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Abstract
Introduction The aim of this study was to assess the efficacy of
arginine-vasopressin (AVP) as a rescue therapy in
catecholamine-refractory septic and non-septic shock in
extremely low birth weight (ELBW) infants with acute renal
injury.
Methods Prospective assessment of AVP therapy in three
ELBW infants with catecholamine-refractory septic shock and
acute renal injury (mean birth weight 600 ± 30 g) and three
ELBW infants with non-septic shock and acute renal injury
(mean birth weight 770 ± 110 g) at a University hospital. The
main outcome measures were restoration of blood pressure with
adequate organ perfusion and survival at discharge.
Results In all three ELBW infants with catecholamine-resistant
septic shock, systemic arterial blood pressure increased
substantively with restoration of urine output after AVP
administration (dosage, 0.035 to 0.36 U/kg/h; length, 70 ± 21
hours). In the three ELBW infants with non-septic shock, only a
transient stabilization in mean arterial pressure with restoration
of urine output was observed after AVP therapy (dosage, 0.01
to 0.36 U/kg/h; length, 30 ± 16 hours). The mortality rate was
1/3 in the sepsis group versus 3/3 in the non-septic group.
Conclusion AVP may be a promising rescue therapy in
catecholamine-resistant shock in ELBW infants with acute renal
injury. Larger prospective clinical trials are warranted to assess
the efficacy and safety of AVP as a pressor adjunct in septic
versus non-septic shock in ELBW infants.
Introduction
Hypotensive, catecholamine-refractory shock is an important
cause of morbidity and mortality in critically ill neonates. There
is general agreement that there is depressed vasoconstrictor
sensitivity to catecholamines in septic shock that can lead to
vasodilatation and severe hypotension. Concentrations of
vasopressin in plasma are significantly depressed in sepsis
while vasopressin secretion is commonly increased in cardio-
genic shock [1]. Clinical data indicate that a low serum vaso-
pressin/norepinephrine ratio can predict impending septic
shock in adults [2]. Recent clinical studies demonstrated that
arginine-vasopressin (AVP) administration is most beneficial in
septic patients [3-9]. However, AVP may also be employed
successfully in children with states of depressed cardiac func-
tion [10].
AVP acts via vascular V1 receptors and renal tubular V2
receptors. V1 receptor stimulation leads to arterial vasocon-
striction, and V2 stimulation increases renal free water re-
absorption. Although no human data are available on V1 and
V2 receptor mechanisms in pre-terms, animal studies demon-
strated that the V1-receptor contributes to renal and cardio-
vascular responses to exogenous AVP in utero at the last third
of gestation [11,12]. Here, we communicate our experience
with AVP as a rescue therapy in six extremely low birth weight
(ELBW) infants with catecholamine-refractory shock (three
septic, three non-septic) and acute renal injury whose hypo-
tension had not responded to prior fluid resuscitation, hydro-
cortisone therapy and high-dose catecholamine infusion.
AVP = arginine-vasopressin; E: Epinephrine; ELBW = extremely low birth weight infants; MAP = mean arterial blood pressure; NE = norepinephrine; 
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Materials and methods
This study was performed at the Department of Neonatology
and Paediatric Intensive Care, University Children's Hospital
of Saarland, and was conducted in accordance with the policy
of our Institutional Review Board and the Helsinki Declaration.
Between February 2004 and November 2005, ELBW infants
(≤ 1,000 g birth weight) with catecholamine-resistant septic or
non-septic shock and acute renal injury were consecutively
enrolled.
Definitions of sepsis and septic shock were based on those
established by the Society of Critical Care Medicine consen-
Table 1
Patient characteristics and clinical details
Patient Age (gender)/
birth weight/
APGAR score
Underlying 
disease/
treatment
Cause/time of 
onset of shock
Urine output/
Increase in 
serum 
creatinine/
Serum lactate 
prior to AVP
Echocardiography Dosage/
duration of AVP
NE/E prior to 
AVP
Further NE/E Clinical outcome/
complications
1 24 + 6 wks (F); 
caesarean 
delivery; 600 g 
APGAR: 7/9/9
RDS, PDA 
Mechanical 
ventilation 
Surgical closure 
of PDA
Klebsiella 
pneumoniae 
sepsis 10th day 
of life
0.2 ml/kg/h 2.3 
times 8.5 mmol/
l
SF: 34–38% After an initial 
bolus of 0.025 
U, 0.035 U/kg/
h 36 hours
NE: 0.5 µg/kg/
minute E: 0.5 
µg/kg/minute
Continuation of 
NE/E over 28 
hours after 
cessation of 
AVP therapy in 
decreasing 
dosage
Survived; BPD; ROP 
II; Two cystic lesions 
(occipital and 
periventricular; 3–4 
mm in diameter) most 
probably residues 
from intracranial 
hemorrhage
2 26 + 5 wks (F); 
caesarean 
delivery; 660 g 
APGAR: 3/7/8
RDS, PDA 
Mechanical 
ventilation 
Surgical closure 
of PDA
Candida 
parapsilosis 
sepsis 12th day 
of life
0.1 ml/kg/h 2.1 
times 14.4 
mmol/
SF: 33–36% 0.10 U/kg/h 
118 hours
NE: 0.5 µg/kg/
minute E: 0.5 
µg/kg/minute
Continuation of 
NE/E over 20 h 
after cessation 
of AVP therapy 
in decreasing 
dosage
Survived; BPD; 
bilateral 
intraventricular 
hemorrhage without 
developing 
hydrocephalus; ROP 
I; no ischemic lesions 
secondary to AVP 
therapy
3 27 + 6 wks (M); 
caesarean 
delivery; 550 g 
APGAR: 6/7/7
RDS, prior 
acute renal 
injury possibly 
related to 
indomethacin 
administration 
Mechanical 
ventilation
E. coli/Staph. 
epidermidis 
sepsis 5th week 
of life
0.2 ml/kg/h 1.5 
times 5.2 mmol/
l
SF: 35–36% Initially 0.12 U/
kg/h, increased 
to 0.36/U/kg/h 
85 hours
NE: 0.5–1.0 
µg/kg/h E: 0.5–
1.0 µg/kg/h
Continuation of 
NE/E over the 
next 6 days 
after cessation 
of AVP therapy 
in increasing 
dosages
Recurrent episode of 
acute renal injury; 
died; autopsy 
showed severe RDS; 
no ischemic lesions 
secondary to AVP 
therapy
4 Twin I: 26 + 1 
wks (M); 
spontaneous 
vaginal delivery; 
890 g APGAR: 
4/7/8
RDS 
Progressive left 
ventricular 
dilatation 
Hyperkalemia 
Pneumothorax 
HFOV Drainage 
of 
pneumothorace
s Intravenous 
calcium, β2-
mimetics, 
insulin
Low-cardiac 
output failure 
3rd day of life
0.2 ml/kg/h 2.0 
times 14.9 
mmol/l
SF: 15–20% 1st 
to 2nd degree 
mitral valve 
insufficiency PDA 
ruled out
Initially 0.01 U/
kg/h, increased 
to 0.1 U/kg/h 
21 hours
NE: 1.5 µg/kg/
minute E: 1.5 
µg/kg/minute
Despite AVP 
increased 
demand for 
catecholamines 
(NE/E: 3 µg/kg/
minute)
Died after 21 hours of 
AVP therapy of 
cardio-respiratory 
failure; no ischemic 
lesions secondary to 
AVP therapy. A 
congenital cardiac 
malformation and 
cardiomyopathy were 
ruled out by autopsy
5 Twin II: 26+1 
wks (M); 
spontaneous 
vaginal delivery; 
880 g APGAR: 
6/7/7
PIE Progressive 
left ventricular 
dilatation 
Hyperkalemia 
HFOV 
Intravenous 
calcium, β2-
mimetics, 
insulin
Low-cardiac 
output failure 
3rd day of life
0.4 ml/kg/h 2.2 
times 20.0 
mmol/l
SF: 15–20% 1st 
to 2nd degree 
mitral valve 
insufficiency PDA 
ruled out
Initially 0.01 U/
kg/h, increased 
to 0.03 U/kg/h 
8 hours
NE: 3.0 µg/kg/
minute E: 3.0 
µg/kg/minute 
Enoximone: 5 
µg/kg/minute
Despite AVP 
increased 
demand for 
catecholamines 
(NE/E: 5 µg/kg/
minute)
Died after 8 hours of 
AVP therapy of 
cardio-respiratory 
failure; no ischemic 
lesions secondary to 
AVP therapy. A 
congenital cardiac 
malformation and 
cardiomyopathy were 
ruled out by autopsy
6 Twin I: 24 + 5 
wks (F); 
caesarean 
delivery; 550 g 
APGAR: 1/5/7
RDS Bilateral 
pneumothorace
s Second 
degree 
intracranial 
hemorrhage 
Mechanical 
ventilation 
Drainage of 
pneumothorace
s
Non-septic 
circulatory 
collapse 
secondary to 
primary disease 
6th day of life
0.3 ml/kg/h 2.7 
times 10.9 
mmol/l
SF: 32–34% Initially 0.12 U/
kg/h, increased 
to 0.36 U/kg/h 
61 hours
NE: 0.4 µg/kg/
minute E: 0.4 
µg/kg/minute
Despite AVP 
catecholamines 
(NE/E: 0.6–0.8 
µg/kg/minute)
Died after 61 hours of 
AVP medication; liver 
tissue necrosis seen 
on autopsy as a 
possible sequelae of 
AVP medication
AVP, arginine-vasopressin; BPD: Bronchopulmonary dysplasia; E, epinephrine; F, female; HFOV, high frequency oscillatory ventilation; M, male; NE, 
norepinephrine; PDA, persistant ductus arteriosus; PIE, pulmonary interstitial emphysema; RDS, respiratory distress syndrome; ROP, retinopathy of 
prematurity; SF, shortening fraction.Available online http://ccforum.com/content/10/3/R71
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sus conference of 1992 and its revised version published in
2003 with modification for normal values in neonates [13,14].
Non-septic shock was defined as cardio-circulatory failure
with concomitant organ dysfunction (renal injury, hyperlacta-
taemia) without an infectious etiology. Low cardiac output was
defined as a shortening fraction ≤ 25%. Acute renal injury was
based on the RIFLE classification, and included two criteria:
glomerular filtration rate (two fold increase in serum creatinine)
or urine output <0.5 ml/kg/h for at least six hours [15].
To maintain adequate systemic perfusion, all infants received
norepinephrine (NE) and epinephrine (E) in a dose-up manner
according to clinical judgements specific to each case, ade-
quate volume resuscitation and hydrocortisone. Diuretic med-
ication consisted of furosemide in varying dosage (0.5 to 2
mg/kg/h). AVP medication was started when patients devel-
oped catecholamine-resistant hypotension with inadequate
tissue perfusion as demonstrated by acute renal injury and
hyperlactataemia (>3 mmol/l). The AVP target dose was 0.01
to 0.12 U/kg/h. The dosage was adjusted according to the
clinical course and included AVP bolus if the mean arterial
blood pressure (MAP) was < 20 mmHg. After restoration of
MAP and urine output, tapering of AVP was attempted.
Stenosis of the renal artery, renal vein thrombosis and post-
renal causes for renal injury were excluded in all infants by
ultrasonography. Serial echocardiography was performed in
all infants to assess left ventricular function. All infants had an
arterial line in place for invasive monitoring of arterial blood
pressure. Daily laboratory monitoring included arterial blood
gas analyses, serum lactate, complete blood count, serum
chemistry and microbiological testing for infectious agents
(bacterial, fungal, viral) as indicated.
Exclusion criteria to AVP administration included genetic dis-
orders, malformations and diseases incompatible with life,
birth weight and weight when included into this study > 1,000
Figure 1
Cardiovascular parameters and urine output and serum lactate in  ELBW infants with sepsis before and after initiation of arginine-vaso- pressin therapy Cardiovascular parameters and urine output and serum lactate in 
ELBW infants with sepsis before and after initiation of arginine-vaso-
pressin therapy. (a) Cardiovascular parameters: columns show mean 
arterial blood pressure (MAP; mmHg); lines show heart rate (beats per 
minute). Values given as mean ± standard deviation. (b) Urine output 
and serum lactate: columns show urine output (ml/kg body weight/h); 
lines show serum lactate (mmol/l). Values given as mean ± standard 
deviation.
Figure 2
Cardiovascular parameters and urine output and serum lactate in  ELBW infants with sepsis before and after initiation of arginine-vaso- pressin therapy Cardiovascular parameters and urine output and serum lactate in 
ELBW infants with sepsis before and after initiation of arginine-vaso-
pressin therapy. (a) Cardiovascular parameters: columns show mean 
arterial blood pressure (MAP; mmHg); lines show heart rate (beats per 
minute). Values given as mean ± standard deviation. (b) Urine output 
and serum lactate: columns show urine output (ml/kg body weight/h); 
lines show serum lactate (mmol/l). Values given as mean ± standard 
deviation.Critical Care    Vol 10 No 3    Meyer et al.
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g, sustained cardio-circulatory function by catecholamine
administration, uncontrolled haemorrhage, prior hypersensitiv-
ity reaction to any constituent of AVP and failure to obtain
parental informed consent. Infants with stenosis of the renal
artery, renal vein thrombosis and post-renal causes of acute
renal injury were also excluded as were infants with cardio-cir-
culatory failure caused by an underlying cardiac pathology that
required specific surgical intervention.
Main outcome measures were restoration of blood pressure
with adequate organ perfusion and survival at discharge.
Results
Between February 2004 and November 2005 a total of six
ELBW infants with catecholamine-resistant septic (two bacte-
rial and one fungal infection) and non-septic shock (two car-
diogenic and one circulatory failure secondary to primary
disease) and acute renal injury were consecutively enrolled in
this study. All infants completed the study protocol. Demo-
graphic and clinical details are summarized in Table 1.
AVP dosage was comparable between septic (0.035 to 0.36
U/kg/h) and non-septic (0.01 to 0.36 U/kg/h) infants. Infant 1
was given an initial bolus of AVP (0.025 U) because of severe
hypotension (MAP < 20 mmHg). The overall length of AVP
administration was 70 ± 21 hours in infants with sepsis versus
30 ± 16 hours in non-septic infants. These differences are due
to the early deaths of two twins with cardiogenic shock
In all six infants, MAP substantially increased within two hours
after AVP administration (Figures 1a and 2a). In infants with
septic shock, the increase in MAP was paralleled by a moder-
ate decrease in heart rate, while in non-septic shock, the heart
rate increased (Figures 1a and 2a).
At the beginning of AVP medication, all six infants were oligo-
anuric. In parallel with the rise in MAP, two hours after starting
AVP urine output increased substantially in all six infants (Fig-
ures 1b and 2b). However, the rise in urine output was not as
pronounced in the two twins with cardiogenic shock (approxi-
mately 3 ml/kg/h). Following restoration of MAP, a pronounced
decrease in serum lactate was seen in infants 1 and 2 with
septic shock while it remained unchanged in infant 3. On the
contrary, serum lactate continued to increase despite AVP in
the two twins with cardiogenic shock. In infant 6, a transient,
non-sustained decrease in serum lactate concentration was
noticed.
Possible adverse effects related to AVP medication are
detailed in Table 1. No acute side effects were seen (for exam-
ple, digital and splanchnic hypoperfusion, abdominal disten-
sion, bloody stools, necrotizing enterocolitis), or myocardial
ischemia, or worsening of metabolic/lactic acidosis that could
be related to AVP administration.
The mortality rate was 1/3 in infants with sepsis-induced cate-
cholamine-refractory shock compared to 3/3 in non-septic
shock infants.
Discussion
As reported in previous studies in children and adults [3-10],
we demonstrated that AVP raised blood pressure in both sep-
tic and non-septic infants that was resistant to catecholamines
(Figures 1a and 2a). Following restoration of tissue perfusion,
a substantial increase in urine output was seen, which is in
accordance with recent reports in children and adults with
septic shock [3,9,16]. In our study, cardiovascular and renal
changes induced by AVP were more pronounced and sus-
tained in infants with septic shock, and associated with a fall
in serum lactate (Figure 1b). The mortality rate in this group
was 1/3. On the contrary, in non-septic infants, only a transient
stabilization in cardiovascular and renal function could be
achieved (Figure 2a,b). AVP administration did not have an
impact on the poor prognosis of the three infants with non-
septic catecholamine-resistant hypotension (mortality rate 3/
3). The difference in survival rates between septic and non-
septic infants cannot be related to the gestational age, birth
weight or APGAR score. At the time of starting AVP, however,
the three ELBW infants with non-septic catecholamine-resist-
ant shock were in poorer clinical condition as shown by sub-
stantially higher serum lactate concentrations and the need for
excessive catecholamines (Table 1).
There is still no clear concept of when to start VPA therapy in
catecholamine-resistant (septic) shock. Recently, a large clin-
ical study in adults with septic shock demonstrated the bene-
ficial effects of initiating AVP therapy before NE requirements
exceed 0.6 µg/kg/minute [17]. This is in accordance with our
data, as the two surviving infants received NE and E in a dos-
age <0.6 µg/kg/minute prior to AVP medication (Table 1).
Interestingly, a recent study in animals demonstrated that the
combined infusion of NE and AVP improves hemodynamic var-
iables compared with NE alone during sepsis, but not during
cardiopulmonary resuscitation [18].
The differential effect of AVP can be related in part to its deple-
tion in septic shock patients with hypersensitivity to exoge-
nous AVP, whereas endogenous AVP release is increased in
cardiogenic shock, causing a decreased response to exoge-
nous AVP [1]. A low plasma AVP/NE ratio appears to be use-
ful in predicting septic shock in adults [2]. In a recent study in
children with meningococcal septic shock, however, AVP
admission levels were appropriately elevated [19]. As we did
not measure AVP serum levels, the above suggested mecha-
nisms remain somewhat speculative. However, the prior
administration of steroids in our study cohort might have
affected endogenous AVP levels because cortisol suppresses
the secretion of AVP in certain conditions [20]. Another limita-
tion is the fact that systemic vascular resistances could not be
determined in our ELBW infants, and thus it cannot be con-Available online http://ccforum.com/content/10/3/R71
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cluded with certainty that refractory shock was associated
with vasoparalysis.
In most pediatric and adult clinical trials that assessed the effi-
cacy of AVP in septic shock, terlipressin, an analogue of AVP
with a longer duration of action (half-life of six hours versus six
minutes for AVP), was given intermittently and not as a contin-
uous infusion [4,7,21]. As hemodynamic profiles may change
rapidly in children with septic shock – that is, transformation
from hyperdynamic to hypodynamic shock with high systemic
vascular resistance [21] – the use of AVP with a shorter time
of action seems more appropriate. In one study in children with
vasodilatory shock after cardiac surgery, AVP dosage ranged
from 0.018 U/kg/h to 0.12 U/kg/h [10]. In another study in
adults with vasodilatory septic shock, AVP was given at a rate
of 2.4 U/h independent of body weight [6]. In our patients,
AVP was administered as a continuous infusion, and titrated to
the dosage that restored MAP and renal excretory function. In
four infants, the mean dosage was in accordance with the
above listed reports; AVP dosage escalation, which was in
excess of standard dosage, was necessary in only two infants
(non-survivors).
Major side effects of concern associated with AVP therapy are
tissue hypoperfusion (mainly splanchnic) and a rebound phe-
nomenon in vascular hyporeactivity with recurrent arterial
hypotension [21,22]. No immediate side effects were seen in
the surviving infants. In one infant (patient 6), substantial tissue
liver necrosis was seen on autopsy, which could be related to
prolonged AVP medication. With NE and E medication being
continued after cessation of AVP, no rebound of clinical signif-
icance in arterial hypotension was noticed in our study cohort.
Conclusion
This report adds further clinical experience on the use of AVP
in catecholamine-refractory shock, indicating that it is also effi-
cacious in ELBW infants. AVP may be a viable rescue therapy
for ELBW infants in a refractory vasodilatatory state and acute
renal injury when conventional therapies fail. To delineate the
role of AVP in catecholamine-resistant shock in ELBW infants,
further assessment of AVP safety and efficacy as a pressor
adjunct in septic versus non-septic shock is warranted.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SM was responsible for the conception and study design and
data acquisition and analysis. SG was involved in data inter-
pretation and drafting the manuscript. AB was responsible for
data acquisition and interpretion of data. DW was responsible
for data acquisition and drafting the manuscript. LG was
involved in data interpretation and drafting the manuscript.
References
1. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Ales-
sandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes
to the vasodilation of septic shock.  Circulation 1997,
95:1122-1125.
2. Lin IY, Ma HP, Lin AC, Chong CF, Lin CM, Wang TL: Low plasma
vasopressin/norepinephrine ratio predicts septic shock.  Am J
Emerg Med 2005, 23:718-724.
3. Masutani S, Senzaki H, Ishido H, Taketazu M, Matsunaga T, Koba-
yashi T, Sasaki N, Asano H, Kyo S, Yokote Y: Vasopressin in the
treatment of vasodilatory shock in children.  Pediatr Int 2005,
47:132-136.
4. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-
resistant septic shock.  Lancet 2002, 359:1209-1210.
5. Liedel JL, Meadow W, Nachman J, Koogler T, Kahana MD: Use of
vasopressin in refractory hypotension in children with vasodi-
latatory shock: Five cases and a review of the literature.  Pedi-
atr Crit Care Med 2002, 3:15-18.
6. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y,
Boyle WA 3rd: Hemodynamic and metabolic effects of low-
dose vasopressin infusions in vasodilatatory septic shock.
Crit Care Med 2001, 29:673-675.
7. Matok I, Leibovitch L, Vardi A, Adam M, Rubinshtein M, Barzilay Z,
Paret G: Terlipressin as a rescue therapy for intractable hypo-
tension during neonatal septic shock.  Pediatr Crit Care Med
2004, 5:116-118.
8. Vasudevan A, Lodha R, Kabra SK: Vasopressin infusion in chil-
dren with catecholamine-resistant septic shock.  Acta Paediatr
2005, 94:380-383.
9. Matok I, Vard A, Efrati E, Rubinshtein M, Vishne T, Leiboitch L,
Adam M, Barzilay Z, Paret G: Terlipressin as a rescue therapy
for intractable hypotension due to septic shock in children.
Shock 2005, 23:305-310.
10. Rosenzweig EB, Starc TJ, Chen JM, Culliane S, Timchak DM, Ger-
sony WM, Landry DW, Galantowicz ME: Intravenous arginine-
vasopressin in children with vasodilatatory shock after cardiac
surgery.  Circulation 1999, 100:II182-II186.
11. Erwin MG, Ross MG, Leake RD, Fisher DA: V1- and V2-receptor
contributions to ovine fetal renal and cardiovascular
responses to vasopressin.  Am J Physiol 1992, 262:R636-643.
12. Shi L, Guerra C, Yao J, Xu Z: Vasopressin mechanism-mediated
pressor responses caused by central angiotensin II in the
ovine fetus.  Pediatr Res 2004, 56:756-762.
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, FEIN AM, Knaus WA,
Schein RM, Sibbad WJ: Definitions for sepsis and organ failure
and guidelines for the use of innovative therapies in sepsis.
The ACCP/SCCM Consensus Conference Committee. Ameri-
can College of Chest Physicians/Society of Critical Care
Medicine.  Chest 1992, 101:1644-1655.
14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D,
Cohen SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/
SIS International Sepsis Conference.  Crit Care Med 2003,
31:1250-1256.
15. Bellomo R, Ronco C, Kellum JA, Mehta R, Palevsky P, the ADQI
workgroup: Acute renal failure-definition, outcome measures,
animal models, fluid therapy and information technology
needs: the Second International Consensus Conference of the
Acute Dialysis Quality Initiative (ADQI) Group.  Crit Care 2004,
8:R204-212.
16. Albanèse J, Leone M, Delmas A, Martin C: Terlipressin or nore-
pinephrine in hyperdynamic septic shock: A prospective, ran-
domized study.  Crit Care Med 2005, 33:1897-1902.
17. Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer
H, Schmid S, Knotzer H, Pajk W, Hasibeder W, et al.: Arginine
Key messages
•  AVP may be a viable rescue therapy for ELBW infants 
with intractable vasodilatation and acute renal injury to 
improve systemic arterial blood pressure and restore 
urine output when conventional inotropics fail.
•  Further evaluation of AVP in larger controlled clinical tri-
als is warranted to assess its efficacy and safety in sep-
tic versus non-septic shock in ELBW infants.Critical Care    Vol 10 No 3    Meyer et al.
Page 6 of 6
(page number not for citation purposes)
vasopressin in 316 patients with advanced vasodilatatory
shock.  Crit Care Med 2005, 33:2659-2666.
18. Prengel AW, Linstedt U, Zenz M, Wenzel V: Effects of combined
administration of vasopressin, epinephrine, and norepine-
phrine during cardiopulmonary resuscitation in pigs.  Crit Care
Med 2005, 33:2587-2591.
19. Leclerc F, Walter-Nicolet E, Leteurtre S, Noizet O, Sadik A, Cremer
R, Fourier C: Admission plasma vasopressin levels in children
with meningococcal septic shock.  Intensive Care Med 2003,
29:1339-1344.
20. Papanek PE, Sladek CD, Raff H: Corticosterone inhibition of
osmotically stimulated vasopressin from hypothalamic-neuro-
hypophysial explants.  Am J Physiol 1997, 272:R158-R162.
21. Berg RA: A long-acting vasopressin analog for septic shock:
Brilliant idea or dangerous folly?  Pediatr Crit Care Med 2004,
5:188-189.
22. Wilson SJ, Mehta SS, Bellamy MC: The safety and efficacy of the
use of vasopressin in sepsis and septic shock.  Expert Opin
Drug Saf 2005, 4:1027-1039.